

Jawahar Lal Mehta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7364549/publications.pdf>

Version: 2024-02-01

517
papers

30,505
citations

4641

85
h-index

6979

154
g-index

544
all docs

544
docs citations

544
times ranked

39213
citing authors

#	ARTICLE	IF	CITATIONS
1	NF- κ B, A Potential Therapeutic Target in Cardiovascular Diseases. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 571-584.	1.3	16
2	Does aspirin save lives in patients with COVID-19?. <i>Heart</i> , 2022, 108, 88-89.	1.2	5
3	Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis. <i>American Journal of Cardiology</i> , 2022, 162, 209-211.	0.7	3
4	Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases. <i>Vaccines</i> , 2022, 10, 232.	2.1	21
5	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2022, 21, 20.	2.7	36
6	PEGylated Gold Nanoparticle Toxicity in Cardiomyocytes: Assessment of Size, Concentration, and Time Dependency. <i>IEEE Transactions on Nanobioscience</i> , 2022, 21, 387-394.	2.2	5
7	Association of Lipid Levels With COVID-19 Infection, Disease Severity and Mortality: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 862999.	1.1	19
8	Persistent cardiac injury “An important component of long COVID-19 syndrome. <i>EBioMedicine</i> , 2022, 77, 103892.	2.7	4
9	Cerebral venous thrombosis after COVID-19 vaccines: Do we know the mechanism?. <i>Lancet Regional Health - Europe</i> , The, 2022, 16, 100387.	3.0	3
10	LOX-1: Implications in atherosclerosis and myocardial ischemia.. <i>EXCLI Journal</i> , 2022, 21, 273-278.	0.5	1
11	The structural basis of effective LOX-1 inhibition. <i>Future Medicinal Chemistry</i> , 2022, , .	1.1	0
12	Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis. <i>Kidney360</i> , 2022, 3, 1374-1383.	0.9	1
13	Vegetarianism, microbiota, and cardiovascular health: looking back, and forward. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1895-1910.	0.8	11
14	Exploring the druggability of oxidized low-density lipoprotein (ox-LDL) receptor, LOX-1, a proatherogenic drug target involved in atherosclerosis. <i>Biochemical and Biophysical Research Communications</i> , 2022, 623, 59-65.	1.0	5
15	Syndemic: A Synergistic Anthropological Approach to the COVID-19 Pandemic. <i>Encyclopedia</i> , 2022, 2, 1344-1356.	2.4	6
16	HDL cholesterol levels and susceptibility to COVID-19. <i>EBioMedicine</i> , 2022, 82, 104166.	2.7	11
17	Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 179-188.	1.0	19
18	Hypothesis: Sex-Related Differences in ACE2 Activity May Contribute to Higher Mortality in Men Versus Women With COVID-19. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 114-118.	1.0	31

#	ARTICLE	IF	CITATIONS
19	Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes—Systematic review and meta-analysis of randomized placebo-controlled trials. <i>American Heart Journal</i> , 2021, 232, 10-22.	1.2	75
20	Letter in response to “COVID-19, Virchow's triad and thromboembolic risk in obese pregnant women”. <i>Clinical Cardiology</i> , 2021, 44, 595-595.	0.7	3
21	Heparan sulfate consumption as a potential mechanism of intra-cardiac thrombosis in SARS-CoV-2 infection. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2021, 50, 242-243.	0.8	2
22	Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19. <i>American Journal of Cardiology</i> , 2021, 142, 158-159.	0.7	52
23	Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. <i>American Heart Journal</i> , 2021, 233, 86-91.	1.2	38
24	Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19. <i>American Journal of Cardiology</i> , 2021, 145, 170-172.	0.7	23
25	Insights on Kawasaki disease and multisystem inflammatory syndrome: relationship with COVID-19 infection. <i>Minerva Pediatrics</i> , 2021, 73, .	0.2	11
26	Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, .	0.6	10
27	Proteomic basis of modulation of post ischemic fibrosis by MSC exosomes. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2021, 321, R639-R654.	0.9	3
28	Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis. <i>Kidney International Reports</i> , 2021, 6, 2381-2391.	0.4	5
29	Hepatic Interactions in Atherosclerotic Heart Disease. <i>American Journal of the Medical Sciences</i> , 2021, , .	0.4	1
30	COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. <i>Pediatric Reports</i> , 2021, 13, 530-533.	0.5	19
31	COVID-19 Vaccine and Myocarditis. <i>American Journal of Cardiology</i> , 2021, 157, 146-148.	0.7	67
32	Loneliness and Social Isolation: Determinants of Cardiovascular Outcomes. <i>Current Cardiology Reviews</i> , 2021, 17, .	0.6	6
33	MSC exosome-mediated cardioprotection in ischemic mouse heart comparative proteomics of infarct and peri-infarct areas. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1691-1704.	1.4	20
34	Insights on Kawasaki disease and multisystem inflammatory syndrome: relationship with COVID-19 infection. <i>Minerva Pediatrics</i> , 2021, 73, 203-208.	0.2	6
35	LOX-1 Deletion Attenuates Myocardial Fibrosis in the Aged Mice, Particularly Those With Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 736215.	1.1	5
36	Gender differences, outcomes and trends among nonagenarian with atrial fibrillation: insight from National Inpatient Sample database. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 114-122.	0.2	0

#	ARTICLE	IF	CITATIONS
37	How to treat left ventricular thrombi- Warfarin or direct oral anti-coagulants?. American Heart Journal Plus, 2021, 13, 100075.	0.3	0
38	How to treat left ventricular thrombi - Warfarin or direct oral anti-coagulants?. American Heart Journal Plus, 2021, 13, 100078.	0.3	0
39	Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines. Cardiovascular Research, 2020, 116, 1721-1732.	1.8	42
40	Chronotherapy for hypertension: improvement in patient outcomes with bedtime administration of antihypertensive drugs. European Heart Journal, 2020, 41, 4577-4579.	1.0	9
41	PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovascular Research, 2020, 116, 908-915.	1.8	115
42	Artificial Intelligence, Machine Learning, and Cardiovascular Disease. Clinical Medicine Insights: Cardiology, 2020, 14, 117954682092740.	0.6	70
43	Daytime or Nighttime Administration of Antihypertensive Medications?. American Journal of Hypertension, 2020, 33, 987-989.	1.0	3
44	Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 503-507.	1.0	12
45	Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications. Journal of Cardiovascular Medicine, 2020, 21, 630-633.	0.6	13
46	Takotsubo cardiomyopathy and COVID-19 infection. European Heart Journal Cardiovascular Imaging, 2020, 21, 1299-1300.	0.5	20
47	Utility of Inferior Lead Q-waveforms in diagnosing Ventricular Tachycardia. Clinical Medicine Insights: Cardiology, 2020, 14, 117954682095341.	0.6	2
48	The Effect of Anticoagulation Use on Mortality in COVID-19 Infection. American Journal of Cardiology, 2020, 134, 155-157.	0.7	14
49	Meta-analysis of Cardiovascular Events and Related Biomarkers Comparing Survivors Versus Non-survivors in Patients With COVID-19. American Journal of Cardiology, 2020, 135, 50-61.	0.7	31
50	COVID-19, thromboembolic risk, and Virchow's triad: Lesson from the past. Clinical Cardiology, 2020, 43, 1362-1367.	0.7	42
51	Suicide, Depression, and Cardiovascular Disease. JACC: Heart Failure, 2020, 8, 519.	1.9	2
52	NLRP3 inflammasome <i>via</i> IL-1 β regulates PCSK9 secretion. Theranostics, 2020, 10, 7100-7110.	4.6	51
53	Coronavirus disease 2019 infection and the cardiovascular system. Journal of Cardiovascular Medicine, 2020, 21, 403-405.	0.6	12
54	Aspirin for prevention of colorectal cancer in the elderly: friend or foe?. Annals of Gastroenterology, 2020, 34, 1-11.	0.4	8

#	ARTICLE	IF	CITATIONS
55	LOX-1 is the prime target for mesenchymal stem cell exosome mediated cardioprotective effects. FASEB Journal, 2020, 34, 1-1.	0.2	0
56	Implications of renal ACE2 expression in the age of COVID-19. European Heart Journal, 2020, 41, 4589-4591.	1.0	3
57	Vitamin E and its anticancer effects. Critical Reviews in Food Science and Nutrition, 2019, 59, 2831-2838.	5.4	106
58	LOX-1: Regulation, Signaling and Its Role in Atherosclerosis. Antioxidants, 2019, 8, 218.	2.2	139
59	Premature birth, infections, and atherosclerotic cardiovascular disease. European Heart Journal, 2019, 40, 3275-3275.	1.0	3
60	Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis. Cardiovascular Drugs and Therapy, 2019, 33, 511-521.	1.3	5
61	Response to "Late repercussions of assisted reproductive technology". European Heart Journal, 2019, 40, 3656-3656.	1.0	1
62	Epigenetic Modification in Coronary Atherosclerosis. Journal of the American College of Cardiology, 2019, 74, 1352-1365.	1.2	71
63	Thiamin therapy for chronic heart failure: is there any future for this vitamin?. American Journal of Clinical Nutrition, 2019, 110, 1270-1271.	2.2	4
64	Aspirin for Primary Prevention of Cardiovascular Events. Journal of the American College of Cardiology, 2019, 73, 2915-2929.	1.2	89
65	Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 428-434.	1.0	16
66	Mechanisms linking preterm birth to onset of cardiovascular disease later in adulthood. European Heart Journal, 2019, 40, 1107-1112.	1.0	64
67	Molecular events in MSC exosome mediated cytoprotection in cardiomyocytes. Scientific Reports, 2019, 9, 19276.	1.6	18
68	Assessing medication adherence. Journal of Hypertension, 2019, 37, 683-684.	0.3	2
69	Aspirin for primary prevention in the elderly. Aging, 2019, 11, 6618-6619.	1.4	8
70	Role of Ox-LDL and LOX-1 in Atherogenesis. Current Medicinal Chemistry, 2019, 26, 1693-1700.	1.2	211
71	Oxidant Stress in Atherosclerosis: Oxidatively Modified LDL and LOX-1. , 2019, , 363-373.		0
72	Inflammation, Autophagy, and Apoptosis After Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	1.6	180

#	ARTICLE	IF	CITATIONS
73	PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. Cardiovascular Research, 2018, 114, 1145-1153.	1.8	88
74	Can certain infections protect against atherosclerosis?. European Heart Journal, 2018, 39, 1654-1654.	1.0	1
75	Multiple admissions to the coronary care unit due to falsely elevated cardiac troponin. Baylor University Medical Center Proceedings, 2018, 31, 197-199.	0.2	3
76	MicroRNA-98 regulates foam cell formation and lipid accumulation through repression of LOX-1. Redox Biology, 2018, 16, 255-262.	3.9	35
77	Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Research in Cardiology, 2018, 113, 5.	2.5	202
78	Mitochondrial Autophagy and NLRP3 Inflammasome in Pulmonary Tissues from Severe Combined Immunodeficient Mice after Cardiac Arrest and Cardiopulmonary Resuscitation. Chinese Medical Journal, 2018, 131, 1174-1184.	0.9	7
79	OBSOLETE: Infective Endocarditis in the 21st Century. , 2018, , .		0
80	Fish, Fish Oils and Cardioprotection: Promise or Fish Tale?. International Journal of Molecular Sciences, 2018, 19, 3703.	1.8	46
81	PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy. Cardiovascular Research, 2018, 114, 1738-1751.	1.8	96
82	Metabolic syndrome emerges after artificial selection for low baroreflex sensitivity. CNS Neuroscience and Therapeutics, 2018, 24, 828-836.	1.9	7
83	Thiamine Therapy for Heart Failure: a Promise or Fiction?. Cardiovascular Drugs and Therapy, 2018, 32, 313-317.	1.3	13
84	Infective Endocarditis in 21st Century. , 2018, , 94-101.		0
85	Xanthine Oxidase Induces Foam Cell Formation through LOX-1 and NLRP3 Activation. Cardiovascular Drugs and Therapy, 2017, 31, 19-27.	1.3	31
86	Controversies in postoperative atrial fibrillation after noncardiothoracic surgery: clinical and research implications. Clinical Cardiology, 2017, 40, 329-332.	0.7	22
87	Role of Inflammation in Heart Failure. Current Atherosclerosis Reports, 2017, 19, 27.	2.0	202
88	Aspirin-Mediated Acetylation Protects Against Multiple Neurodegenerative Pathologies by Impeding Protein Aggregation. Antioxidants and Redox Signaling, 2017, 27, 1383-1396.	2.5	44
89	LOX-1 in Atherosclerosis and Myocardial Ischemia. Journal of the American College of Cardiology, 2017, 69, 2759-2768.	1.2	132
90	Trials of Angiogenesis Therapy in Patients with Ischemic Heart Disease. , 2017, , 393-421.		0

#	ARTICLE	IF	CITATIONS
91	Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 593-608.	1.3	83
92	Oxidative Stress in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2017, 19, 42.	2.0	825
93	Angiogenesis and Atherosclerosis. , 2017, , 361-376.		0
94	Functions of MicroRNAs in Angiogenesis. , 2017, , 133-155.		0
95	Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention. <i>American Journal of Cardiology</i> , 2017, 120, 1122-1128.	0.7	19
96	Transcatheter mitral valve replacement with a novel self-expandable prosthesis. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 415-424.	0.6	10
97	The Impact of Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement on Left Ventricular Remodeling. <i>American Journal of Cardiology</i> , 2017, 120, 1198-1202.	0.7	8
98	Cardiovascular complications of multiple myeloma in the elderly. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 933-943.	0.6	16
99	Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2017, 11, 215-225.	1.0	577
100	Infections, atherosclerosis, and coronary heart disease. <i>European Heart Journal</i> , 2017, 38, 3195-3201.	1.0	185
101	Vascular Remodeling in Diabetes Mellitus. , 2017, , 73-93.		3
102	Immuno-Inflammatory Basis of Atherosclerotic Coronary Artery Disease. , 2016, , 23-32.		0
103	Endothelial cell dysfunction as a novel therapeutic target in atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1021-1033.	0.6	63
104	MiR-590-5p Inhibits Oxidized- LDL Induced Angiogenesis by Targeting LOX-1. <i>Scientific Reports</i> , 2016, 6, 22607.	1.6	29
105	Inflammation in Heart Failure. <i>Hypertension</i> , 2016, 68, 27-29.	1.3	22
106	Modulation of myocardial injury and collagen deposition following ischaemiaâ€reperfusion by linagliptin and liraglutide, and both together. <i>Clinical Science</i> , 2016, 130, 1353-1362.	1.8	27
107	Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 1349-1358.	2.8	23
108	PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering. <i>Atherosclerosis</i> , 2016, 253, 275-277.	0.4	18

#	ARTICLE	IF	CITATIONS
109	Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. <i>Science Immunology</i> , 2016, 1, .	5.6	560
110	Reply. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2090-2091.	1.2	2
111	Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 997-1008.	2.5	63
112	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
113	Age- and Hypertension-Associated Protein Aggregates in Mouse Heart Have Similar Proteomic Profiles. <i>Hypertension</i> , 2016, 67, 1006-1013.	1.3	72
114	Neighborhood and Acute Myocardial Infarction Mortality as Related to the Driving Time to Percutaneous Coronary Interventionâ€œCapable Hospital. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	14
115	Scavenger receptors and non-coding RNAs: relevance in atherogenesis. <i>Cardiovascular Research</i> , 2016, 109, 24-33.	1.8	23
116	Cardiac drug therapy-considerations in the elderly. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 992-997.	0.2	10
117	Gender Differences in Autonomic Control of the Cardiovascular System. <i>Current Pharmaceutical Design</i> , 2016, 22, 3829-3834.	0.9	29
118	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1202-1203.	1.2	9
119	Tocopherols in the Prevention and Treatment of Atherosclerosis and Related Cardiovascular Disease. <i>Clinical Cardiology</i> , 2015, 38, 570-576.	0.7	90
120	Structure-based Design Targeted at LOX-1, a Receptor for Oxidized Low-Density Lipoprotein. <i>Scientific Reports</i> , 2015, 5, 16740.	1.6	42
121	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2157.	1.2	0
122	Heavy Ethanol Consumption Aggravates the Ischemic Cerebral Injury by Inhibiting ALDH2. <i>International Journal of Stroke</i> , 2015, 10, 1261-1269.	2.9	18
123	Metabolic Syndrome: Does it Differ Between Women and Men?. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 329-338.	1.3	116
124	Gender-Related Differences in Atherosclerosis. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 319-327.	1.3	80
125	LOX-1 in macrophage migration in response to ox-LDL and the involvement of calpains. <i>Biochemical and Biophysical Research Communications</i> , 2015, 467, 135-139.	1.0	19
126	Comparison of Angiographic Burden of Coronary Artery Disease in Patients With Versus Without Hepatitis CÂInfection. <i>American Journal of Cardiology</i> , 2015, 116, 1041-1044.	0.7	17

#	ARTICLE	IF	CITATIONS
127	Endothelin-1 upregulation mediates aging-related cardiac fibrosis. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 80, 101-109.	0.9	54
128	Hemodynamic shear stress modulates endothelial cell autophagy: Role of LOX-1. <i>International Journal of Cardiology</i> , 2015, 184, 86-95.	0.8	27
129	Hemodynamic Shear Stress <i>via</i> ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 760-771.	2.5	160
130	Tobacco and Cardiovascular Health. <i>Cardiovascular Toxicology</i> , 2015, 15, 107-116.	1.1	25
131	The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 265-275.	1.3	12
132	Degradation of HSPGs Enhances LOX-1-mediated Autophagy. , 2015, , 209-218.		0
133	Cross-talk between LOX-1 and PCSK9 in vascular tissues. <i>Cardiovascular Research</i> , 2015, 107, 556-567.	1.8	192
134	Trends in Infective Endocarditis Incidence, Microbiology, and Valve Replacement in the United States From 2000 to 2011. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2070-2076.	1.2	488
135	Gene and MicroRNA Transcriptional Signatures of Angiotensin II in Endothelial Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 65, 123-129.	0.8	13
136	Lectin-like oxidized low-density lipoprotein receptor-1 regulates autophagy and Toll-like receptor 4 in the brain of hypertensive mice. <i>Journal of Hypertension</i> , 2015, 33, 525-533.	0.3	14
137	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1847-1848.	1.2	0
138	Unique Aspects of Coronary Artery Disease in Indian Women. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 369-376.	1.3	12
139	Women and Heart Disease; A Focus Issue. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 317-318.	1.3	2
140	Lectin-Like ox-LDL Receptor-1 (LOX-1)â€“Toll-Like Receptor 4 (TLR4) Interaction and Autophagy in CATH.a Differentiated Cells Exposed to Angiotensin II. <i>Molecular Neurobiology</i> , 2015, 51, 623-632.	1.9	13
141	Our obsession with saturated fats: is it time to rethink their role in the coronary artery disease?. <i>Clinical Lipidology</i> , 2014, 9, 287-290.	0.4	0
142	Prevention of export of anoxia/reoxygenation injury from ischemic to nonischemic cardiomyocytes via inhibition of endocytosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 306, H1700-H1707.	1.5	8
143	Hypertension, TLR4 activation in brain and cardiac hypertrophy. <i>Cardiovascular Research</i> , 2014, 103, 3-4.	1.8	10
144	Impact of Hepatitis C Seropositivity on the Risk of Coronary Heart Disease Events. <i>American Journal of Cardiology</i> , 2014, 114, 1841-1845.	0.7	69

#	ARTICLE	IF	CITATIONS
145	High Fat Diet Causes Renal Fibrosis in LDLr-null Mice Through MAPK-NF- κ B Pathway Mediated by Ox-LDL. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 63, 158-166.	0.8	18
146	GLP-1 Agonists Inhibit ox-LDL Uptake in Macrophages by Activating Protein Kinase A. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 64, 47-52.	0.8	30
147	LOX-1 Deletion Limits Cardiac Angiogenesis in Mice Given Angiotensin II. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 441-446.	1.3	12
148	Can autologous bone marrow transplantation improve systolic function in patients with multiple myeloma related cardiac amyloidosis?. <i>International Journal of Cardiology</i> , 2014, 172, 265-266.	0.8	3
149	DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway. <i>Acta Diabetologica</i> , 2014, 51, 471-478.	1.2	33
150	MicroRNA-29, a Mysterious Regulator in Myocardial Fibrosis and Circulating miR-29a as a Biomarker. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2181.	1.2	17
151	Do We Know Why Deaths from Heart Disease Have Declined?. <i>American Journal of Cardiology</i> , 2014, 114, 1627.	0.7	0
152	DPP-4 Inhibitors Repress NLRP3 Inflammasome and Interleukin-1beta via GLP-1 Receptor in Macrophages Through Protein Kinase C Pathway. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 425-432.	1.3	95
153	Intracellular NAMPT \rightarrow NAD \rightarrow SIRT1 cascade improves post-ischaeamic vascular repair by modulating Notch signalling in endothelial progenitors. <i>Cardiovascular Research</i> , 2014, 104, 477-488.	1.8	64
154	LOX-1 \rightarrow dependent mitochondrial DNA damage and NLRP3 activation during systemic inflammation in mice. <i>Biochemical and Biophysical Research Communications</i> , 2014, 451, 637-643.	1.0	7
155	Inflammation and Atherosclerosis \rightarrow Revisited. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 170-178.	1.0	164
156	Interaction of carbamylated LDL with LOX-1 in the induction of endothelial dysfunction and atherosclerosis: Figure 1. <i>European Heart Journal</i> , 2014, 35, 2996-2997.	1.0	13
157	Optimal Blood Pressure in Patients With Atrial Fibrillation (from the AFFIRM Trial). <i>American Journal of Cardiology</i> , 2014, 114, 727-736.	0.7	34
158	LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis. <i>Cardiovascular Research</i> , 2014, 103, 619-628.	1.8	111
159	LOX-1, oxidant stress, mtDNA damage, autophagy, and immune response in atherosclerosis. <i>Canadian Journal of Physiology and Pharmacology</i> , 2014, 92, 524-530.	0.7	40
160	Contemporary Trends of Hospitalization for Atrial Fibrillation in the United States, 2000 Through 2010. <i>Circulation</i> , 2014, 129, 2371-2379.	1.6	365
161	Role of cardiac CTA in estimating left ventricular volumes and ejection fraction. <i>World Journal of Radiology</i> , 2014, 6, 669.	0.5	23
162	Bilateral common carotid artery ultrasound for prediction of incident strokes using intima-media thickness and external diameter: an observational study. <i>Cardiovascular Ultrasound</i> , 2013, 11, 22.	0.5	14

#	ARTICLE	IF	CITATIONS
163	Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach. <i>Acta Diabetologica</i> , 2013, 50, 827-835.	1.2	14
164	Regulation of autophagy and apoptosis in response to angiotensin II in HL-1 cardiomyocytes. <i>Biochemical and Biophysical Research Communications</i> , 2013, 440, 696-700.	1.0	33
165	LOX-1 deletion and macrophage trafficking in atherosclerosis. <i>Biochemical and Biophysical Research Communications</i> , 2013, 440, 210-214.	1.0	21
166	Local immune activity in acute coronary syndrome: oxLDL abrogates LPS-tolerance in mononuclear cells isolated from culprit lesion. <i>International Journal of Cardiology</i> , 2013, 169, 44-51.	0.8	5
167	Regulation of MSR-1 and CD36 in macrophages by LOX-1 mediated through PPAR- γ . <i>Biochemical and Biophysical Research Communications</i> , 2013, 431, 496-500.	1.0	23
168	LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 437, 62-66.	1.0	40
169	National trends in case fatality based on anatomical location of ST elevation myocardial infarction, 1993 – 2010. <i>International Journal of Cardiology</i> , 2013, 168, 3017-3018.	0.8	1
170	All CAD Is Not CHD, and All CHD Is Not CAD. <i>Journal of the American College of Cardiology</i> , 2013, 61, 387-388.	1.2	0
171	Aspirin Inhibits Oxidant Stress, Reduces Age-Associated Functional Declines, and Extends Lifespan of <i>Caenorhabditis elegans</i> . <i>Antioxidants and Redox Signaling</i> , 2013, 18, 481-490.	2.5	98
172	Involvement of Arterial Baroreflex in the Protective Effect of Dietary Restriction Against Stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 906-913.	2.4	21
173	LOX-1 in the maintenance of cytoskeleton and proliferation in senescent cardiac fibroblasts. <i>Journal of Molecular and Cellular Cardiology</i> , 2013, 60, 184-190.	0.9	19
174	Regulation of autophagy and apoptosis in response to ox-LDL in vascular smooth muscle cells, and the modulatory effects of the microRNA hsa-let-7g. <i>International Journal of Cardiology</i> , 2013, 168, 1378-1385.	0.8	138
175	Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 371-380.	1.3	87
176	The Neighborhood Where You Live Is a Risk Factor for Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 668-673.	0.9	14
177	MicroRNAs Involved in the Regulation of Postischemic Cardiac Fibrosis. <i>Hypertension</i> , 2013, 61, 751-756.	1.3	32
178	Oxidant stress in mitochondrial DNA damage, autophagy and inflammation in atherosclerosis. <i>Scientific Reports</i> , 2013, 3, 1077.	1.6	159
179	ALDH2 protects against stroke by clearing 4-HNE. <i>Cell Research</i> , 2013, 23, 915-930.	5.7	148
180	Is irisin an early marker of statin-induced myopathy? Bench to the bedside. <i>Clinical Lipidology</i> , 2013, 8, 623-625.	0.4	3

#	ARTICLE	IF	CITATIONS
181	Concentration polarization of ox-LDL activates autophagy and apoptosis via regulating LOX-1 expression. <i>Scientific Reports</i> , 2013, 3, 2091.	1.6	26
182	Angiogenesis in Atherosclerosis: An Overview. , 2013, , 209-224.		1
183	Potential Mechanisms Linking Oxidized LDL to Susceptibility to Cancer. , 2013, , 357-379.		0
184	Abrogation of lectin-like oxidized LDL receptor-1 attenuates acute myocardial ischemia-induced renal dysfunction by modulating systemic and local inflammation. <i>Kidney International</i> , 2012, 82, 436-444.	2.6	30
185	Cholesterol-Induced Membrane Microvesicles As Novel Carriers of Damage-Associated Molecular Patterns. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2113-2121.	1.1	62
186	Dual AAV/IL-10 Plus STAT3 Anti-Inflammatory Gene Delivery Lowers Atherosclerosis in LDLR KO Mice, but without Increased Benefit. <i>International Journal of Vascular Medicine</i> , 2012, 2012, 1-7.	0.4	12
187	Aspirin Downregulates Angiotensin Type 1 Receptor Transcription Implications in Capillary Formation From Endothelial Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 60, 187-192.	0.8	6
188	Adherence junction proteins in angiogenesis. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 187-193.	0.6	8
189	The LOX-1 scavenger receptor and its implication in coronary artery disease. <i>Clinical Lipidology</i> , 2012, 7, 271-273.	0.4	2
190	Lectin-like Oxidized Low-density Lipoprotein Receptor-1 (LOX-1) and Cardiac Fibroblast Growth. <i>Hypertension</i> , 2012, 60, 1437-1442.	1.3	19
191	MicroRNA hsa-let-7g targets lectin-like oxidized low-density lipoprotein receptor-1 expression and inhibits apoptosis in human smooth muscle cells. <i>Experimental Biology and Medicine</i> , 2012, 237, 1093-1100.	1.1	35
192	Degradation of heparan sulfate proteoglycans enhances oxidized-LDL-mediated autophagy and apoptosis in human endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 426, 106-111.	1.0	20
193	Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2012, 6, 229-236.	1.0	30
194	Prevalence of Takotsubo cardiomyopathy in the United States. <i>American Heart Journal</i> , 2012, 164, 66-71.e1.	1.2	324
195	Functional characterization and expression analysis of novel alternative splicing isoforms of Olr1 gene during mouse embryogenesis. <i>Gene</i> , 2012, 491, 5-12.	1.0	5
196	Severe Obesity and ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1731-1732.	1.2	0
197	Cross-talk between inflammation and angiotensin II: Studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA. <i>Experimental Biology and Medicine</i> , 2012, 237, 1394-1401.	1.1	37
198	Large Impact of Low Concentration Oxidized LDL on Angiogenic Potential of Human Endothelial Cells: A Microarray Study. <i>PLoS ONE</i> , 2012, 7, e47421.	1.1	28

#	ARTICLE	IF	CITATIONS
199	Cannabinoids and Atherosclerotic Coronary Heart Disease. <i>Clinical Cardiology</i> , 2012, 35, 329-335.	0.7	72
200	Assessing the Credibility of the "YouTube Approach" to Health Information on Acute Myocardial Infarction. <i>Clinical Cardiology</i> , 2012, 35, 281-285.	0.7	120
201	Current Concepts of the Role of Oxidized LDL Receptors in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2012, 14, 150-159.	2.0	105
202	Association of Hypertension and Anti-Hypertensive Therapy with Cancers. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 261-266.	0.8	0
203	Delineation of the effects of angiotensin type 1 and 2 receptors on HL-1 cardiomyocyte apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2012, 17, 908-915.	2.2	16
204	Comparison of Outcomes of Weekend Versus Weekday Admissions for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2012, 110, 208-211.	0.7	52
205	Aspirin suppresses cardiac fibroblast proliferation and collagen formation through downregulation of angiotensin type 1 receptor transcription. <i>Toxicology and Applied Pharmacology</i> , 2012, 259, 346-354.	1.3	31
206	Oxidized LDL Triggers Pro-Oncogenic Signaling in Human Breast Mammary Epithelial Cells Partly via Stimulation of MiR-21. <i>PLoS ONE</i> , 2012, 7, e46973.	1.1	38
207	Prior exposure to oxidized low-density lipoprotein limits apoptosis in subsequent generations of endothelial cells by altering promoter methylation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H506-H513.	1.5	39
208	Triad of Metabolic Syndrome, Chronic Kidney Disease, and Coronary Heart Disease With a Focus on Microalbuminuria. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2303-2308.	1.2	34
209	Oxidative Stress and Lectin-Like Ox-LDL-Receptor LOX-1 in Atherogenesis and Tumorigenesis. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 2301-2333.	2.5	151
210	Oxidized LDL Receptor 1 (OLR1) as a Possible Link between Obesity, Dyslipidemia and Cancer. <i>PLoS ONE</i> , 2011, 6, e20277.	1.1	96
211	Potential Involvement of LOX-1 in Functional Consequences of Endothelial Senescence. <i>PLoS ONE</i> , 2011, 6, e20964.	1.1	38
212	Oxidized Low-Density Lipoprotein and Atherosclerosis Implications in Antioxidant Therapy. <i>American Journal of the Medical Sciences</i> , 2011, 342, 135-142.	0.4	166
213	Change in Mortality from Coronary Heart Disease and Stroke in Arkansas (1979 to 2007). <i>American Journal of Cardiology</i> , 2011, 107, 156-160.	0.7	5
214	Determining the Significance of Side Branch Lesion During Bifurcation Stenting. <i>American Journal of Cardiology</i> , 2011, 107, 1794-1795.	0.7	3
215	Effect of Joint National Committee VII Report on Hospitalizations for Hypertensive Emergencies in the United States. <i>American Journal of Cardiology</i> , 2011, 108, 1277-1282.	0.7	79
216	LOX-1 Transcription. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 393-400.	1.3	27

#	ARTICLE	IF	CITATIONS
217	LOX-1: A New Target for Therapy for Cardiovascular Diseases. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 495-500.	1.3	15
218	LOX-1: A Critical Player in the Genesis and Progression of Myocardial Ischemia. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 431-440.	1.3	23
219	Do Atherosclerosis and Obesity-Associated Susceptibility to Cancer Share Causative Link to oxLDL and LOX-1?. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 477-487.	1.3	11
220	LOX-1 and Angiotensin Receptors, and Their Interplay. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 401-17.	1.3	36
221	LOX-1 and Obesity. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 469-476.	1.3	27
222	Novel Concepts in the Genesis of Hypertension: Role of LOX-1. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 441-449.	1.3	22
223	Oxidized LDL, LOX-1 and Atherosclerosis. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 419-429.	1.3	247
224	LOX-1, Oxidative Stress and Inflammation: A Novel Mechanism for Diabetic Cardiovascular Complications. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 451-459.	1.3	58
225	Angiogenesis is a Link Between Atherosclerosis and Tumorigenesis: Role of LOX-1. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 461-468.	1.3	25
226	Statins and Renal Disease: Friend or Foe?. <i>Current Atherosclerosis Reports</i> , 2011, 13, 57-63.	2.0	3
227	In vivo flow cytometry of circulating clots using negative photothermal and photoacoustic contrasts. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2011, 79A, 814-824.	1.1	44
228	Decorin in atherosclerosis. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 305-314.	1.0	11
229	Angiostatic Effects of Aspirin in Hypoxia-Reoxygenation Are Linked to Modulation of TGF β 21 Signaling. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2011, 16, 105-110.	1.0	9
230	Nanomedicine in Cardiovascular Diseases: Emerging Diagnostic and Therapeutic Potential. <i>Journal of Nanotechnology in Engineering and Medicine</i> , 2011, 2, .	0.8	3
231	Curcumin Reduces Angiotensin II-mediated Cardiomyocyte Growth via LOX-1 Inhibition. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 55, 176-183.	0.8	45
232	Antiangiogenic and Antimitotic Effects of Aspirin in Hypoxiaâ€œReoxygenation Modulation of the LOX-1-NADPH Oxidase Axis as a Potential Mechanism. <i>Journal of Cardiovascular Pharmacology</i> , 2010, 56, 635-641.	0.8	23
233	Racial Disparities in Prescriptions for Cardioprotective Drugs and Cardiac Outcomes in Veterans Affairs Hospitals. <i>American Journal of Cardiology</i> , 2010, 105, 1019-1023.	0.7	26
234	Molecular Imaging of Atherosclerotic Plaques Targeted to Oxidized LDL Receptor LOX-1 by SPECT/CT and Magnetic Resonance. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 464-472.	1.3	110

#	ARTICLE	IF	CITATIONS
235	Antiarrhythmic Drug Therapy vs Catheter Ablation for Paroxysmal Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2010, 303, 1808.	3.8	0
236	Management of dyslipidemia in the elderly population. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 375-383.	1.0	24
237	Genomics of cardiac remodeling in angiotensin II-treated wild-type and LOX-1-deficient mice. Physiological Genomics, 2010, 42, 42-54.	1.0	12
238	Calcium-dependent platelet aggregation through the interaction between phosphatidylserine and LOX-1. Cardiovascular Research, 2010, 88, 547-547.	1.8	0
239	Circulating endothelial progenitor cells, microparticles and vascular disease. Journal of Hypertension, 2010, 28, 1611-1613.	0.3	11
240	Vascular Cav1.2 Expression is Increased in Atherosclerosis. Biophysical Journal, 2010, 98, 695a.	0.2	0
241	Statins and Altered Glucose Metabolism. Journal of the American College of Cardiology, 2010, 56, 680.	1.2	3
242	AAV/hSTAT3-gene delivery lowers aortic inflammatory cell infiltration in LDLR KO mice on high cholesterol. Atherosclerosis, 2010, 213, 59-66.	0.4	18
243	Role of genomics in cardiovascular medicine. World Journal of Cardiology, 2010, 2, 428.	0.5	16
244	Aspirin resistance: Fact or fiction? A point of view. World Journal of Cardiology, 2010, 2, 280.	0.5	15
245	Rosuvastatin Attenuates Ang II Mediated Cardiomyocyte Hypertrophy via Inhibition of LOX-1. Journal of Cardiovascular Pharmacology and Therapeutics, 2009, 14, 283-291.	1.0	32
246	Association of Scavenger Receptors in Adipose Tissue With Insulin Resistance in Nondiabetic Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1328-1335.	1.1	51
247	Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients. Journal of Investigative Medicine, 2009, 57, 495-499.	0.7	106
248	Effect of fish oils containing different amounts of EPA, DHA, and antioxidants on plasma and brain fatty acids and brain nitric oxide synthase activity in rats. Upsala Journal of Medical Sciences, 2009, 114, 206-213.	0.4	38
249	Intracellular Signaling of LOX-1 in Endothelial Cell Apoptosis. Circulation Research, 2009, 104, 566-568.	2.0	74
250	Deletion of LOX-1 attenuates renal injury following angiotensin II infusion. Kidney International, 2009, 76, 521-527.	2.6	28
251	The combination of atenolol and amlodipine is better than their monotherapy for preventing end-organ damage in different types of hypertension in rats. Journal of Cellular and Molecular Medicine, 2009, 13, 726-734.	1.6	14
252	LOX-1 dependent overexpression of immunoglobulins in cardiomyocytes in response to angiotensin II. Biochemical and Biophysical Research Communications, 2009, 379, 395-399.	1.0	25

#	ARTICLE	IF	CITATIONS
253	Statins and angiogenesis: Is it about connections?. Biochemical and Biophysical Research Communications, 2009, 387, 543-547.	1.0	37
254	Currying the Heart: Curcumin and Cardioprotection. Journal of Cardiovascular Pharmacology and Therapeutics, 2009, 14, 22-27.	1.0	98
255	Cardiac Hypertrophy During Hypercholesterolemia and Its Amelioration With Rosuvastatin and Amlodipine. Journal of Cardiovascular Pharmacology, 2009, 54, 327-334.	0.8	38
256	Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis. Journal of Cardiovascular Medicine, 2009, 10, 231-237.	0.6	14
257	Renin Angiotensin System and Atherosclerosis. , 2009, , 215-230.		0
258	Upregulation of Angiotensin II Type 2 Receptor (agtr2) Attenuates Atherosclerotic Lesion Formation and Enhances Apoptosis in the LDL Receptor Knockout Mice Fed High Cholesterol Diet. , 2009, , 151-163.		0
259	Assessment of left ventricular function: comparison of cardiac multidetector-row computed tomography with two-dimension standard echocardiography for assessment of left ventricular function. International Journal of Cardiovascular Imaging, 2008, 24, 317-325.	0.7	29
260	B-mode ultrasound common carotid artery intima-media thickness and external diameter: cross-sectional and longitudinal associations with carotid atherosclerosis in a large population sample. Cardiovascular Ultrasound, 2008, 6, 10.	0.5	31
261	Percutaneous intervention on the saphenous vein bypass graftsâ€™Long-term outcomes. Catheterization and Cardiovascular Interventions, 2008, 71, 58-61.	0.7	40
262	Present Status of Coronary Bifurcation Stenting. Clinical Cardiology, 2008, 31, 63-66.	0.7	9
263	Effect of Statins on the Development of Renal Dysfunction. American Journal of Cardiology, 2008, 101, 975-979.	0.7	43
264	Percutaneous Intervention in Saphenous Vein Bypass Graft Disease. Journal of the American College of Cardiology, 2008, 51, 970-971.	1.2	4
265	LOX-1 abrogation reduces myocardial ischemiaâ€™reperfusion injury in mice. Journal of Molecular and Cellular Cardiology, 2008, 44, 76-83.	0.9	50
266	Over-expression of angiotensin II type 2 receptor (agtr2) decreases collagen accumulation in atherosclerotic plaque. Biochemical and Biophysical Research Communications, 2008, 366, 871-877.	1.0	46
267	Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis, 2008, 199, 288-294.	0.4	56
268	Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations. American Journal of Physiology - Renal Physiology, 2008, 294, F110-F119.	1.3	42
269	LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet. Cardiovascular Research, 2008, 79, 287-293.	1.8	88
270	Erythropoietin in cardioprotection: does it have a future or is it all in the past?. Cardiovascular Research, 2008, 79, 549-550.	1.8	6

#	ARTICLE	IF	CITATIONS
271	Modulation of Angiotensin IIâ€‘Mediated Hypertension and Cardiac Remodeling by Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Deletion. <i>Hypertension</i> , 2008, 52, 556-562.	1.3	73
272	Regulation of TGF β 21-mediated Collagen Formation by LOX-1. <i>Journal of Biological Chemistry</i> , 2008, 283, 10226-10231.	1.6	65
273	Biology of LOX-1 in relation to atherogenesis. <i>Future Lipidology</i> , 2008, 3, 689-696.	0.5	6
274	LOX-1 deletion alters signals of myocardial remodeling immediately after ischemiaâ€‘reperfusion. <i>Cardiovascular Research</i> , 2007, 76, 292-302.	1.8	54
275	Mechanism of action and delivery possibilities for TGF β 21 in the treatment of myocardial ischemia. <i>Cardiovascular Research</i> , 2007, 74, 235-243.	1.8	24
276	Blockade of hypoxia-reoxygenation-mediated collagen type I expression and MMP activity by overexpression of TGF β 21 delivered by AAV in mouse cardiomyocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H1833-H1838.	1.5	25
277	Angiotensin II Induces Capillary Formation From Endothelial Cells Via the LOX-1â€‘Dependent Redox-Sensitive Pathway. <i>Hypertension</i> , 2007, 50, 952-957.	1.3	49
278	A man with four coronary arteries. <i>European Heart Journal</i> , 2007, 28, 1357-1357.	1.0	1
279	High-risk acute coronary syndrome patient and cardiac biomarkers in the emergency department: where do we stand?. <i>European Heart Journal</i> , 2007, 28, 1043-1044.	1.0	4
280	The TGF β 2 superfamily in cardiovascular biology. <i>Cardiovascular Research</i> , 2007, 74, 181-183.	1.8	19
281	Modulation of ADP-Induced Platelet Activation by Aspirin and Pravastatin: Role of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1, Nitric Oxide, Oxidative Stress, and Inside-Out Integrin Signaling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 1324-1332.	1.3	70
282	Deletion of LOX-1 Reduces Atherogenesis in LDLR Knockout Mice Fed High Cholesterol Diet. <i>Circulation Research</i> , 2007, 100, 1634-1642.	2.0	397
283	Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2007, 22, 434-442.	0.8	7
284	Use of statins in the elderly. <i>Future Lipidology</i> , 2007, 2, 9-13.	0.5	0
285	High-risk ACS patients and cardiac biomarkers in the emergency department: any role for new biomarkers of myocardial ischaemia? Reply. <i>European Heart Journal</i> , 2007, 28, 2297-2298.	1.0	0
286	LONG-TERM OUTCOMES OF SINGLE VS MULTIPLE STENT DEPLOYMENT DURING PERCUTANEOUS CORONARY INTERVENTION. <i>Chest</i> , 2007, 132, 542A.	0.4	0
287	CULPRIT LESION SEVERITY IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. <i>Chest</i> , 2007, 132, 544A.	0.4	0
288	LONG-TERM OUTCOMES OF PERCUTANEOUS INTERVENTION ON THE SAPHENOUS VEIN GRAFTS AND THEIR PREDICTORS. <i>Chest</i> , 2007, 132, 468A.	0.4	0

#	ARTICLE	IF	CITATIONS
289	Small Concentrations of oxLDL Induce Capillary Tube Formation From Endothelial Cells via LOX-1-Dependent Redox-Sensitive Pathway. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2435-2442.	1.1	140
290	Multislice Computed Tomography in an Asymptomatic High-Risk Population. <i>American Journal of Cardiology</i> , 2007, 99, 325-328.	0.7	54
291	Inflammatory Markers, Angiographic Severity of Coronary Artery Disease, and Patient Outcome. <i>American Journal of Cardiology</i> , 2007, 99, 879-884.	0.7	67
292	Predictors of In-stent Restenosis and Patient Outcome After Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2007, 100, 777-780.	0.7	33
293	Implantable cardioverter defibrillators for prevention of sudden cardiac Death. <i>Clinical Cardiology</i> , 2007, 30, 3-8.	0.7	6
294	Traditional Risk Factors and Acute Myocardial Infarction in Patients Hospitalized with Cocaine-Associated Chest Pain. <i>Clinical Cardiology</i> , 2007, 30, 290-294.	0.7	22
295	Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1615-1624.	2.0	23
296	Value of CRP in coronary risk determination. <i>Indian Heart Journal</i> , 2007, 59, 173-7.	0.2	1
297	Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis. <i>Atherosclerosis</i> , 2006, 184, 295-301.	0.4	88
298	Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. <i>Atherosclerosis</i> , 2006, 188, 19-27.	0.4	80
299	Suppression of atherogenesis by delivery of si11 . <i>Journal of Cellular Biochemistry</i> , 2006, 100, 115-122.	1.0	37
300	Oxidative stress in diabetes: A mechanistic overview of its effects on atherogenesis and myocardial dysfunction. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 794-803.	1.2	138
301	The role of statins in endothelial dysfunction in hypertension. <i>Current Opinion in Cardiology</i> , 2006, 21, 316-321.	0.8	23
302	OLR1 gene and coronary artery disease/acute myocardial infarction: replication in an independently collected sample. <i>European Journal of Human Genetics</i> , 2006, 14, 894-895.	1.4	6
303	Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease. <i>Current Hypertension Reports</i> , 2006, 8, 139-143.	1.5	21
304	Multiple human papillomavirus genes affect the adeno-associated virus life cycle. <i>Virology</i> , 2006, 344, 532-540.	1.1	19
305	Safety and Effectiveness of Granulocyte-Colony Stimulating Factor in Mobilizing Stem Cells and Improving Cytokine Profile in Advanced Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2006, 97, 681-684.	0.7	22
306	Relation of Microalbuminuria and Coronary Artery Disease in Patients With and Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2006, 98, 279-281.	0.7	49

#	ARTICLE	IF	CITATIONS
307	Enhanced 11 β -Hydroxysteroid Dehydrogenase Activity, the Metabolic Syndrome, and Systemic Hypertension. <i>American Journal of Cardiology</i> , 2006, 98, 544-548.	0.7	24
308	Comparison of Mortality Rates in Statin Users Versus Nonstatin Users in a United States Veteran Population. <i>American Journal of Cardiology</i> , 2006, 98, 923-928.	0.7	38
309	Structural evaluation of radially expandable cardiovascular stents encased in a polyurethane film. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2006, 76B, 241-250.	1.6	24
310	Do we need continuous ECG monitoring in patients transferred for primary angioplasty?The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2006, 27, 249-250.	1.0	2
311	Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) transcriptional regulation by Oct-1 in human endothelial cells: implications for atherosclerosis. <i>Biochemical Journal</i> , 2006, 393, 255-265.	1.7	46
312	Modulation of Atherosclerosis, Blood Pressure and Arterial Elasticity by Statins. , 2006, 44, 315-330.		4
313	Coronary artery restenosis: vascular biology and emerging therapeutic strategies. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 543-556.	0.6	17
314	Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H1738-H1745.	1.5	81
315	Human cytomegalovirus inhibits Akt-mediated eNOS activation through upregulating PTEN (phosphatase and tensin homolog deleted on chromosome 10). <i>Cardiovascular Research</i> , 2006, 69, 502-511.	1.8	43
316	Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model. <i>Cardiovascular Research</i> , 2006, 69, 263-271.	1.8	68
317	Molecular Dissection of Angiotensin II-Activated Human LOX-1 Promoter. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1163-1168.	1.1	38
318	Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): A critical player in the development of atherosclerosis and related disorders. <i>Cardiovascular Research</i> , 2006, 69, 36-45.	1.8	395
319	C-reactive protein and cardiovascular disease: a critical appraisal. <i>Current Opinion in Internal Medicine</i> , 2005, 4, 561-570.	1.5	16
320	Molecular pathology of aging and its implications for senescent coronary atherosclerosis. <i>Current Opinion in Cardiology</i> , 2005, 20, 399-406.	0.8	37
321	Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2565-2576.	0.9	10
322	Aortic stenosis: Is it simply a degenerative process or an active atherosclerotic process?. <i>Clinical Cardiology</i> , 2005, 28, 111-114.	0.7	23
323	Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. <i>Cancer Gene Therapy</i> , 2005, 12, 304-312.	2.2	22
324	Exercise training provides cardioprotection against ischemia-induced reperfusion induced apoptosis in young and old animals. <i>Experimental Gerontology</i> , 2005, 40, 416-425.	1.2	105

#	ARTICLE	IF	CITATIONS
325	On-Chip Antennas in Silicon ICs and Their Application. IEEE Transactions on Electron Devices, 2005, 52, 1312-1323.	1.6	258
326	Relevance of Platelet-independent Effects of Aspirin to Its Salutary Effect in Atherosclerosis-related Events. Journal of Atherosclerosis and Thrombosis, 2005, 12, 185-190.	0.9	32
327	The effects of PPAR- γ ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovascular Research, 2005, 65, 907-912.	1.8	95
328	Oxidized LDL, a critical factor in atherogenesis. Cardiovascular Research, 2005, 68, 353-354.	1.8	113
329	Adhesion Molecule Expression in Fibroblasts. Hypertension, 2005, 46, 622-627.	1.3	32
330	Cardiovascular Risk of Selective Cyclooxygenase-2 Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 2005, 10, 95-101.	1.0	10
331	In Vivo and In Vitro Studies Support That a New Splicing Isoform of OLR1 Gene Is Protective Against Acute Myocardial Infarction. Circulation Research, 2005, 97, 152-158.	2.0	116
332	Statins in the Primary Prevention of Atherosclerosis-Related Events. , 2004, , 53-92.		1
333	Anticoagulant Effects of Statins. , 2004, , 233-256.		0
334	Role of AIF in human coronary artery endothelial cell apoptosis. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H354-H358.	1.5	23
335	Generation of Recombinant Skin in Vitro by Adeno-Associated Virus Type 2 Vector Transduction. Tissue Engineering, 2004, 10, 1707-1715.	4.9	15
336	Role of Caspases in Ox-LDL-Induced Apoptotic Cascade in Human Coronary Artery Endothelial Cells. Circulation Research, 2004, 94, 370-376.	2.0	246
337	Mathematical estimation of the potential effect of vascular remodelling/dilatation on B-mode ultrasound intima-medial thickness. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 729-737.	0.2	11
338	Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events. Circulation, 2004, 109, IV-6-IV-19.	1.6	313
339	Evaluation of Venous and Arterial Conduit Patency by 16-Slice Spiral Computed Tomography. Circulation, 2004, 110, 3234-3238.	1.6	163
340	The Protective Effect of Superoxide Dismutase Mimetic M40401 on Balloon Injury-Related Neointima Formation: Role of the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 44-50.	1.3	37
341	Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts. Hypertension, 2004, 44, 655-661.	1.3	141
342	Actions of Statins on Ox-LDL-Mediated Signaling and Inflammation. , 2004, , 203-218.		0

#	ARTICLE	IF	CITATIONS
343	Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. <i>Cardiovascular Research</i> , 2004, 64, 243-249.	1.8	95
344	New Insights from Trials of Statins in Animal Models of Atherosclerosis. , 2004, , 13-35.		0
345	Tumor Necrosis Factor- α -Induced Apoptosis of Human Coronary Artery Endothelial Cells: Modulation by the Peroxisome Proliferator-Activated Receptor- β Ligand Pioglitazone. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2004, 9, 35-41.	1.0	31
346	Bradycardia during therapy for multiple myeloma with thalidomide. <i>American Journal of Cardiology</i> , 2004, 93, 1052-1055.	0.7	82
347	Dietary recommendations in the prevention and treatment of coronary heart disease: Do we have the ideal diet yet?. <i>American Journal of Cardiology</i> , 2004, 94, 1260-1267.	0.7	77
348	MnSOD antisense treatment and exercise-induced protection against arrhythmias. <i>Free Radical Biology and Medicine</i> , 2004, 37, 1360-1368.	1.3	71
349	Regulatory role of endothelium in the expression of genes affecting arterial calcification. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 424-427.	1.0	85
350	Transforming Growth Factor β 2 Receptor Endoglin Is Expressed in Cardiac Fibroblasts and Modulates Profibrogenic Actions of Angiotensin II. <i>Circulation Research</i> , 2004, 95, 1167-1173.	2.0	132
351	Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. <i>Current Opinion in Cardiology</i> , 2004, 19, 488-493.	0.8	127
352	Potential of gene therapy for myocardial ischemia. <i>Current Opinion in Cardiology</i> , 2004, 19, 517-523.	0.8	6
353	Magnetic resonance imaging in myocardial ischemia. <i>Current Opinion in Cardiology</i> , 2004, 19, 510-516.	0.8	13
354	Metabolic syndrome: dietary interventions. <i>Current Opinion in Cardiology</i> , 2004, 19, 473-479.	0.8	30
355	Inhibitory Effect of Candesartan and Rosuvastatin on CD40 and MMPs Expression in Apo-E Knockout Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, 446-452.	0.8	45
356	Human Urotensin II Modulates Collagen Synthesis and the Expression of MMP-1 in Human Endothelial Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, 577-581.	0.8	41
357	Loss of exercise-induced cardioprotection after cessation of exercise. <i>Journal of Applied Physiology</i> , 2004, 96, 1299-1305.	1.2	119
358	Anoxia-Reoxygenation Stimulates Collagen Type-I and MMP-1 Expression in Cardiac Fibroblasts. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, 682-687.	0.8	50
359	The role of LOX-1, a novel lectin-like receptor for oxidized low density lipoprotein, in atherosclerosis. <i>Canadian Journal of Cardiology</i> , 2004, 20 Suppl B, 32B-36B.	0.8	13
360	Role of oxidative stress in coronary heart disease. <i>Indian Heart Journal</i> , 2004, 56, 163-73.	0.2	36

#	ARTICLE	IF	CITATIONS
361	Effect of a multicomponent, ephedra-containing dietary supplement (Metabolife 356) on Holter monitoring and hemostatic parameters in healthy volunteers. <i>American Journal of Cardiology</i> , 2003, 91, 1510-1513.	0.7	29
362	The adeno-associated virus major regulatory protein Rep78-c-Jun-DNA motif complex modulates AP-1 activity. <i>Virology</i> , 2003, 314, 423-431.	1.1	14
363	Expression of lectin-like oxidized low-density lipoprotein receptors during ischemia-reperfusion and its role in determination of apoptosis and left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1048-1055.	1.2	98
364	Interactions Between the Renin-Angiotensin System and Dyslipidemia. <i>Archives of Internal Medicine</i> , 2003, 163, 1296.	4.3	97
365	EPA and DHA attenuate ox-LDL-induced expression of adhesion molecules in human coronary artery endothelial cells via protein kinase B pathway. <i>Journal of Molecular and Cellular Cardiology</i> , 2003, 35, 769-775.	0.9	67
366	Identification of apoptosis-inducing factor in human coronary artery endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2003, 301, 147-151.	1.0	22
367	Aspirin inhibits human coronary artery endothelial cell proliferation by upregulation of p53. <i>Biochemical and Biophysical Research Communications</i> , 2003, 301, 143-146.	1.0	13
368	Oxidized LDL through LOX-1 modulates LDL-receptor expression in human coronary artery endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 1008-1012.	1.0	20
369	Inflammation, infection, and atherosclerosis. <i>Brain, Behavior, and Immunity</i> , 2003, 17, 238-244.	2.0	25
370	LOX-1 Mediates Oxidized Low-Density Lipoprotein-Induced Expression of Matrix Metalloproteinases in Human Coronary Artery Endothelial Cells. <i>Circulation</i> , 2003, 107, 612-617.	1.6	210
371	LOX-1, an Oxidized LDL Endothelial Receptor, Induces CD40/CD40L Signaling in Human Coronary Artery Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 816-821.	1.1	143
372	Eicosapentanoic acid inhibits hypoxia-reoxygenation-induced injury by attenuating upregulation of MMP-1 in adult rat myocytes. <i>Cardiovascular Research</i> , 2003, 59, 7-13.	1.8	25
373	Pioglitazone Inhibits LOX-1 Expression in Human Coronary Artery Endothelial Cells by Reducing Intracellular Superoxide Radical Generation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 2203-2208.	1.1	121
374	3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors Protect Against Oxidized Low-Density Lipoprotein-Induced Endothelial Dysfunction. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2003, 10, 17-21.	1.7	35
375	Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 575-585.	0.5	109
376	Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells. <i>Cardiovascular Research</i> , 2003, 57, 238-243.	1.8	68
377	Does electron beam computer tomography provide added value in the diagnosis of coronary artery disease?. <i>Current Opinion in Cardiology</i> , 2003, 18, 385-393.	0.8	9
378	Potential Anticancer Effects of Statins: Fact or Fiction?. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2003, 10, 49-58.	1.7	29

#	ARTICLE	IF	CITATIONS
379	Pleiotropic Effects of Statins: How Important Are They in the Prevention of Vascular Disease?. Endothelium: Journal of Endothelial Cell Research, 2003, 10, 3-4.	1.7	9
380	Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood, 2003, 102, 3100-3107.	0.6	51
381	TGF- β ¹ attenuates myocardial ischemia-reperfusion injury via inhibition of upregulation of MMP-1. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H1612-H1617.	1.5	81
382	Identification, Regulation and Function of Lox-1, a Novel Receptor for Ox-Ldl. Progress in Experimental Cardiology, 2003, , 71-81.	0.0	4
383	Peroxisome Proliferator-Activated Receptor Ligands as Antiatherogenic Agents: Panacea or Another Pandora's Box?. Journal of Cardiovascular Pharmacology and Therapeutics, 2002, 7, 1-8.	1.0	8
384	Statins Modulate Oxidized Low-Density Lipoprotein-Mediated Adhesion Molecule Expression in Human Coronary Artery Endothelial Cells: Role of LOX-1. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 601-605.	1.3	170
385	Protection of Myocytes From Hypoxia-Reoxygenation Injury by Nitric Oxide Is Mediated by Modulation of Transforming Growth Factor- β ¹ . Circulation, 2002, 105, 2206-2211.	1.6	30
386	LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H1795-H1801.	1.5	68
387	Angiotensin II and IV Stimulate Expression and Release of Plasminogen Activator Inhibitor-1 in Cultured Human Coronary Artery Endothelial Cells. Journal of Cardiovascular Pharmacology, 2002, 39, 789-794.	0.8	45
388	Does carotid intima media thickness indicate coronary atherosclerosis?. Current Opinion in Cardiology, 2002, 17, 526-530.	0.8	31
389	Potlucks, Probability, and Prevention. Current Opinion in Cardiology, 2002, 17, 493-494.	0.8	0
390	Exercise and cardioprotection. Current Opinion in Cardiology, 2002, 17, 495-502.	0.8	114
391	Management of dyslipidemia in the primary prevention of coronary heart disease. Current Opinion in Cardiology, 2002, 17, 503-511.	0.8	31
392	Dietary modulations in the prevention of coronary artery disease: a special emphasis on vitamins and fish oil. Current Opinion in Cardiology, 2002, 17, 559-567.	0.8	7
393	Modulation of Matrix Metalloproteinase-1, Its Tissue Inhibitor, and Nuclear Factor- κ B by Losartan in Hypercholesterolemic Rabbits. Journal of Cardiovascular Pharmacology, 2002, 39, 332-339.	0.8	33
394	Mixed Tocopherol Preparation Is Superior to α -Tocopherol Alone against Hypoxia-Induced Reoxygenation Injury. Biochemical and Biophysical Research Communications, 2002, 291, 349-353.	1.0	12
395	Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. Journal of the American College of Cardiology, 2002, 39, 1429-1435.	1.2	148
396	Attenuation of Tissue P-Selectin and MCP-1 Expression and Intimal Proliferation by AT1 Receptor Blockade in Hyperlipidemic Rabbits. Biochemical and Biophysical Research Communications, 2001, 282, 474-479.	1.0	20

#	ARTICLE	IF	CITATIONS
397	Inhibition of LOX-1 by Statins May Relate to Upregulation of eNOS. <i>Biochemical and Biophysical Research Communications</i> , 2001, 289, 857-861.	1.0	111
398	Short-term exercise training can improve myocardial tolerance to I/R without elevation in heat shock proteins. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 281, H1346-H1352.	1.5	139
399	TGF- β 1 modulates NOS expression and phosphorylation of Akt/PKB in rat myocytes exposed to hypoxia-reoxygenation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 281, H1035-H1039.	1.5	40
400	Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. <i>Free Radical Biology and Medicine</i> , 2001, 30, 148-153.	1.3	31
401	Transforming Growth Factor- β 1 Modulates Oxidatively Modified LDL-Induced Expression of Adhesion Molecules. <i>Circulation Research</i> , 2001, 89, 1155-1160.	2.0	59
402	Different Isoforms of Tocopherols Enhance Nitric Oxide Synthase Phosphorylation and Inhibit Human Platelet Aggregation and Lipid Peroxidation: Implications in Therapy with Vitamin E. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2001, 6, 155-161.	1.0	47
403	Facilitative interaction between angiotensin II and oxidised LDL in cultured human coronary artery endothelial cells. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, S70-S76.	1.0	8
404	Angiotensin II via Activation of Type 1 Receptor Upregulates Expression of Endoglin in Human Coronary Artery Endothelial Cells. <i>Hypertension</i> , 2001, 38, 1062-1067.	1.3	34
405	Relationship of Chlamydia pneumoniae Infection to Severity of Human Coronary Atherosclerosis. <i>Circulation</i> , 2000, 101, 2568-2571.	1.6	67
406	Nitric oxide synthase in adult red blood cells: Vestige of an earlier age or a biologically active enzyme?. <i>Translational Research</i> , 2000, 135, 430-431.	2.4	12
407	Seropositivity against <i>Chlamydia pneumoniae</i> in patients with coronary atherosclerosis. <i>Clinical Cardiology</i> , 2000, 23, 327-330.	0.7	21
408	Inhibition of Arterial Thrombogenesis by Quinapril but Not Losartan. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2000, 5, 121-127.	1.0	7
409	Antisense to LOX-1 Inhibits Oxidized LDL-Mediated Upregulation of Monocyte Chemoattractant Protein-1 and Monocyte Adhesion to Human Coronary Artery Endothelial Cells. <i>Circulation</i> , 2000, 101, 2889-2895.	1.6	396
410	Oxidized LDL Upregulates Angiotensin II Type 1 Receptor Expression in Cultured Human Coronary Artery Endothelial Cells. <i>Circulation</i> , 2000, 102, 1970-1976.	1.6	192
411	Upregulation of LOX-1 Expression in Aorta of Hypercholesterolemic Rabbits: Modulation by Losartan. <i>Biochemical and Biophysical Research Communications</i> , 2000, 276, 1100-1104.	1.0	122
412	Modulation of Myocardial SOD and iNOS During Ischemia-reperfusion by Antisense Directed at ACE mRNA. <i>Journal of Molecular and Cellular Cardiology</i> , 2000, 32, 2259-2268.	0.9	7
413	Upregulation of Endothelial Receptor for Oxidized LDL (LOX-1) by Oxidized LDL and Implications in Apoptosis of Human Coronary Artery Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1116-1122.	1.1	316
414	Inflammation, Infection and Atherosclerosis. <i>Drugs</i> , 2000, 59, 159-170.	4.9	12

#	ARTICLE	IF	CITATIONS
415	The Potential Role of Antisense Oligodeoxynucleotide Therapy for Cardiovascular Disease. <i>Drugs</i> , 2000, 60, 239-248.	4.9	13
416	Effects of $\hat{\alpha}$ -Tocopherol on ox-LDL-Mediated Degradation of $\hat{\alpha}$ B and Apoptosis in Cultured Human Coronary Artery Endothelial Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, 297-301.	0.8	28
417	Use of Antioxidants in Cardiovascular Medicine. <i>Developments in Cardiovascular Medicine</i> , 2000, , 225-238.	0.1	0
418	Vitamins C and E Prolong Time to Arterial Thrombosis in Rats. <i>Journal of Nutrition</i> , 1999, 129, 109-112.	1.3	34
419	Proapoptotic effects of ANG II in human coronary artery endothelial cells: role of AT1receptor and PKC activation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 276, H786-H792.	1.5	35
420	Modulation of constitutive nitric oxide synthase, bcl-2 and Fas expression in cultured human coronary endothelial cells exposed to anoxiaâ€œreoxygenation and angiotensin II: role of AT1 receptor activation. <i>Cardiovascular Research</i> , 1999, 41, 109-115.	1.8	55
421	Relative Effects of $\hat{\alpha}$ - and $\hat{\beta}$ -Tocopherol on Low-Density Lipoprotein Oxidation and Superoxide Dismutase and Nitric Oxide Synthase Activity and Protein Expression in Rats. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1999, 4, 219-226.	1.0	67
422	Superoxide Anion Generation, Superoxide Dismutase Activity, and Nitric Oxide Release in Human Internal Mammary Artery and Saphenous Vein Segments. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1999, 4, 249-257.	1.0	15
423	Inhibition of Arterial Thrombus Formation by ApoA1 Milano. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 378-383.	1.1	138
424	Differential effects of $\hat{\alpha}$ - and $\hat{\beta}$ -tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. <i>Journal of the American College of Cardiology</i> , 1999, 34, 1208-1215.	1.2	198
425	Kinetics of tumor necrosis factor $\hat{\alpha}$ in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor $\hat{\alpha}$ in acute myocardial infarction. <i>American Heart Journal</i> , 1999, 137, 1145-1152.	1.2	88
426	$\hat{\beta}$ -Tocopherol Decreases Ox-LDL-Mediated Activation of Nuclear Factor- $\hat{\alpha}$ B and Apoptosis in Human Coronary Artery Endothelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1999, 259, 157-161.	1.0	56
427	Tumor necrosis factor- $\hat{\alpha}$ enhances hypoxiaâ€œreoxygenation-mediated apoptosis in cultured human coronary artery endothelial cells: critical role of protein kinase C. <i>Cardiovascular Research</i> , 1999, 42, 805-813.	1.8	35
428	Modulation of arterial thrombosis by angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade. <i>American Journal of Cardiology</i> , 1998, 82, 53S-56S.	0.7	6
429	Modulation of arterial thrombosis by angiotensin-converting enzyme inhibition and angiotensin II type 1-receptor blockade. <i>American Journal of Cardiology</i> , 1998, 82, S53-S56.	0.7	0
430	Interactive Role of Infection, Inflammation and Traditional Risk Factors in Atherosclerosis and Coronary Artery Disease 11This study was supported in part by a Merit Review grant from the Department of Veterans Affairs Central Office, Washington, D.C.. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1217-1225.	1.2	283
431	Identification and Autoregulation of Receptor for OX-LDL in Cultured Human Coronary Artery Endothelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1998, 248, 511-514.	1.0	171
432	Increased Angiotensin II Type 1 Receptor Expression in Hypercholesterolemic Atherosclerosis in Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1433-1439.	1.1	129

#	ARTICLE	IF	CITATIONS
433	Share the Research, Not Taxpayers' Income. <i>Chest</i> , 1998, 114, 947.	0.4	1
434	Funding for Biomedical Research. <i>Chest</i> , 1998, 113, 565-566.	0.4	1
435	Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 275, H568-H576.	1.5	76
436	Analysis of responses to adrenomedullin-(13â€”52) in the pulmonary vascular bed of rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 274, H1255-H1263.	1.5	12
437	Melagatran, An Oral Active-Site Inhibitor of Thrombin, Prevents or Delays Formation of Electrically Induced Occlusive Thrombus in the Canine Coronary Artery. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, 345-351.	0.8	70
438	INHIBITION OF NITRIC OXIDE DOES NOT AFFECT REPERFUSION-INDUCED MYOCARDIAL INJURY, BUT IT PREVENTS LIPID PEROXIDATION IN THE ISOLATED RAT HEART. <i>Life Sciences</i> , 1997, 61, 229-236.	2.0	17
439	Preservation of Endogenous Antioxidant Activity and Inhibition of Lipid Peroxidation as Common Mechanisms of Antiatherosclerotic Effects of Vitamin E, Lovastatin and Amlodipine. <i>Journal of the American College of Cardiology</i> , 1997, 30, 569-575.	1.2	197
440	Effects of Exercise-Induced Oxidative Stress on Nitric Oxide Release and Antioxidant Activity. <i>American Journal of Cardiology</i> , 1997, 80, 1640-1642.	0.7	24
441	Alterations in circulating intercellular adhesion molecule-1 and L-selectin: Further evidence for chronic inflammation in ischemic heart disease. <i>American Heart Journal</i> , 1996, 132, 1-8.	1.2	184
442	Cardioprotective Effects of Red Blood Cells on Ischemia and Reperfusion Injury in Isolated Rat Heart: Release of Nitric Oxide as a Potential Mechanism. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1996, 1, 297-306.	1.0	26
443	Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. <i>Translational Research</i> , 1996, 127, 287-295.	2.4	29
444	Oxidized LDL Decreases L-Arginine Uptake and Nitric Oxide Synthase Protein Expression in Human Platelets. <i>Circulation</i> , 1996, 93, 1740-1746.	1.6	146
445	Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis. <i>Cardiovascular Research</i> , 1995, 30, 866-874.	1.8	11
446	Decrease in hematocrit after coronary stent placement and dextran therapy. <i>American Journal of Cardiology</i> , 1995, 76, 314-315.	0.7	8
447	Oxidized Low-Density Lipoproteins Facilitate Leukocyte Adhesion to Aortic Intima Without Affecting Endothelium-Dependent Relaxation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 2076-2083.	1.1	61
448	Myocardial neutrophil infiltration, lipid peroxidation, and antioxidant activity after coronary artery thrombolysis and thrombolysis. <i>American Heart Journal</i> , 1995, 129, 211-218.	1.2	41
449	Endothelium, coronary vasodilation, and organic nitrates. <i>American Heart Journal</i> , 1995, 129, 382-391.	1.2	72
450	Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction. <i>American Heart Journal</i> , 1995, 130, 692-697.	1.2	17

#	ARTICLE	IF	CITATIONS
451	Amlodipine in chronic stable angina: Results of a multicenter double-blind crossover trial. <i>American Heart Journal</i> , 1995, 129, 527-535.	1.2	48
452	Reduction of nitric oxide synthase activity in human neutrophils by oxidized low-density lipoproteins. <i>Biochemical Pharmacology</i> , 1995, 50, 1181-1185.	2.0	16
453	Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs. <i>Journal of the American College of Cardiology</i> , 1995, 25, 753-760.	1.2	11
454	Replacement of L-Lys by D-Lys(NH ₂) in Peptide Ala-Arg-Pro-Ala-Lys (Peptide 6A) Increases Its Coronary Blood Flow-Promoting Properties. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 23, 103-106.	0.8	1
455	Effects of fish oil on some parameters of fibrinolysis and lipoprotein(a) in healthy subjects. <i>American Journal of Cardiology</i> , 1994, 74, 189-192.	0.7	30
456	Emerging options in the management of myocardial ischemia. <i>American Journal of Cardiology</i> , 1994, 73, A18-A27.	0.7	11
457	Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 1994, 74, 662-666.	0.7	19
458	Potential therapeutic implications of the phenomenon of ischemic preconditioning of the myocardium: Lessons from the animal and catheterization laboratories. <i>American Journal of Cardiology</i> , 1994, 74, 1270-1271.	0.7	4
459	Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. <i>American Journal of Cardiology</i> , 1994, 74, 901-905.	0.7	88
460	Attenuation of coronary flow reserve and myocardial function after temporary subtotal coronary artery occlusion and increased myocardial oxygen demand in dogs. <i>Journal of the American College of Cardiology</i> , 1994, 24, 795-803.	1.2	12
461	Adenosine protects against attenuation of flow reserve and myocardial function after coronary occlusion and reperfusion. <i>American Heart Journal</i> , 1994, 127, 1201-1211.	1.2	14
462	Failure of brief ischemic episodes to protect against myocardial dysfunction caused by ischemia and reperfusion in isolated rat hearts. <i>American Heart Journal</i> , 1994, 128, 1192-1200.	1.2	9
463	Reduction in human neutrophil superoxide anion generation by n-3 polyunsaturated fatty acids: Role of cyclooxygenase products and endothelium-derived relaxing factor. <i>Thrombosis Research</i> , 1994, 76, 317-322.	0.8	62
464	Lys-and Glu-plasminogen potentiate the inhibitory effect of recombinant tissue plasminogen activator on human platelet aggregation. <i>Thrombosis Research</i> , 1994, 74, 555-563.	0.8	18
465	Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. <i>Life Sciences</i> , 1994, 55, 1815-1821.	2.0	56
466	Decreased endothelium-dependent vascular relaxation following subtotal coronary artery occlusion in dogs. <i>Free Radical Biology and Medicine</i> , 1993, 14, 295-302.	1.3	9
467	Increased production of thromboxane A ₂ by coronary arteries after thrombolysis. <i>American Heart Journal</i> , 1993, 125, 277-284.	1.2	23
468	Long-term dietary fish oil supplementation protects against ischemia-reperfusion-induced myocardial dysfunction in isolated rat hearts. <i>American Heart Journal</i> , 1993, 126, 1287-1292.	1.2	51

#	ARTICLE	IF	CITATIONS
469	Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. American Heart Journal, 1993, 125, 1704-1710.	1.2	21
470	Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs. American Heart Journal, 1993, 126, 285-292.	1.2	10
471	Verapamil and aspirin modulate platelet-mediated vasomotion in arterial segments with intact or disrupted endothelium. Journal of the American College of Cardiology, 1993, 22, 684-689.	1.2	16
472	Effects of aspirin in arterial thrombosis: Why don't animals behave the way humans do?. Journal of the American College of Cardiology, 1993, 21, 511-513.	1.2	8
473	Modulation of vascular tone by endothelin-1: role of preload, endothelial integrity and concentration of endothelin-1. British Journal of Pharmacology, 1992, 106, 127-132.	2.7	16
474	Agonist-induced tension determines vascular reactivity during anoxia and reoxygenation. Life Sciences, 1992, 50, 1805-1812.	2.0	10
475	Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator. Journal of the American College of Cardiology, 1992, 20, 228-235.	1.2	51
476	Co-purification of 130 KD nitric oxide synthase and A 22 KD link protein from human neutrophils. Biochemical and Biophysical Research Communications, 1992, 189, 558-564.	1.0	44
477	Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis. American Heart Journal, 1992, 124, 280-288.	1.2	28
478	Diagnostic and therapeutic implications: Exploration through case discussions. American Journal of Cardiology, 1992, 70, F45-F48.	0.7	0
479	Prevalence of coronary artery disease in Asian Indians. American Journal of Cardiology, 1992, 70, 945-949.	0.7	211
480	Platelet-leukocyte-endothelial interactions in coronary artery disease. American Journal of Cardiology, 1992, 69, B8-B13.	0.7	31
481	Role of superoxide radicals in anoxia and reoxygenation-mediated vascular contraction. Life Sciences, 1991, 49, 1739-1746.	2.0	21
482	Concurrent nitroglycerin administration decreases thrombolytic potential of tissue-type plasminogen activator. Journal of the American College of Cardiology, 1991, 17, 805-811.	1.2	19
483	Leukocyte elastase inhibition and t-PA-induced coronary artery thrombolysis in dogs: Beneficial effects on myocardial histology. American Heart Journal, 1991, 122, 1245-1251.	1.2	30
484	Recovery of vascular smooth muscle relaxation from nitroglycerin-induced tolerance following a drug-free interval. Biochemical Pharmacology, 1991, 41, 743-747.	2.0	5
485	Angiotensin converting enzyme inhibitors potentiate the vasorelaxant effect of fibrinogen-derived peptide 6A. Thrombosis Research, 1991, 61, 81-85.	0.8	4
486	Polymorphonuclear leukocytes relax human internal mammary artery and saphenous vein segments differently. Coronary Artery Disease, 1991, 2, 379-388.	0.3	5

#	ARTICLE	IF	CITATIONS
487	Effects of amlodipine on blood pressure, heart rate, catecholamines, lipids and responses to adrenergic stimulus. <i>American Journal of Cardiology</i> , 1990, 66, 1269-1271.	0.7	31
488	Coronary reperfusion in dogs inhibits endothelium-dependent relaxation: Role of superoxide radicals. <i>Free Radical Biology and Medicine</i> , 1990, 8, 373-380.	1.3	28
489	Iloprost and tissue-type plasminogen activator differently affect platelet aggregation in platelet-rich plasma and in whole blood. <i>Thrombosis Research</i> , 1990, 60, 337-342.	0.8	8
490	Leukotriene-receptor antagonist FPL-55712 and t-PA-induced thrombolysis in canine coronary thrombosis. <i>Thrombosis Research</i> , 1990, 58, 13-21.	0.8	6
491	Reduction in human neutrophil chemotaxis by the prostacyclin analogue iloprost. <i>Thrombosis Research</i> , 1990, 59, 669-674.	0.8	15
492	Relaxation of human internal mammary artery rings by neutrophils: Evidence for generation of an EDRF-like compound. <i>Journal of the American College of Cardiology</i> , 1990, 15, A180.	1.2	1
493	Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1990, 15, 1559-1563.	1.2	172
494	Atypical creatine kinase MB isozyme in an elderly patient without evidence of myocardial infarction or underlying malignancy. <i>American Heart Journal</i> , 1990, 119, 693-694.	1.2	2
495	Inhibitory effect of unstimulated neutrophils on platelet aggregation by release of a factor similar to Endothelium-Derived Relaxing Factor (EDRF). <i>Biochemical Pharmacology</i> , 1990, 40, 2265-2269.	2.0	16
496	Evidence for generation of a large amount of nitric oxide-like vascular smooth muscle relaxant by cholesterol-rich neutrophils. <i>Biochemical and Biophysical Research Communications</i> , 1990, 173, 438-442.	1.0	12
497	Endothelial, platelet and leukocyte interactions in ischemic heart disease: Insights into potential mechanisms and their clinical relevance. <i>Journal of the American College of Cardiology</i> , 1990, 16, 207-222.	1.2	159
498	Platelet activation in unstable angina: Role of thromboxane A2 and other mediators of vasoconstriction. <i>Journal of the American College of Cardiology</i> , 1990, 15, 727-729.	1.2	8
499	Generation of superoxide radicals and release of elastase by neutrophils during thrombolysis. <i>Journal of the American College of Cardiology</i> , 1990, 15, A32.	1.2	5
500	Prophylactic aspirin use among US physicians. <i>American Journal of Cardiology</i> , 1989, 63, 370-372.	0.7	4
501	Tissue plasminogen activator and plasmin independently decrease human neutrophil activation. <i>Life Sciences</i> , 1989, 45, 1665-1669.	2.0	10
502	Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease. <i>American Journal of Medicine</i> , 1988, 84, 45-52.	0.6	89
503	Modulation of human neutrophil superoxide production by selective thromboxane synthetase inhibitor U63, 557A. <i>Life Sciences</i> , 1988, 43, 923-928.	2.0	20
504	Neutrophils as potential participants in acute myocardial ischemia: Relevance to reperfusion. <i>Journal of the American College of Cardiology</i> , 1988, 11, 1309-1316.	1.2	237

#	ARTICLE	IF	CITATIONS
505	Cimetidine does not increase alpha 1â€œacid glycoprotein serum concentrations.. British Journal of Clinical Pharmacology, 1988, 25, 514-517.	1.1	2
506	Plasma Lipid Profiles and Antihypertensive Agents: Effects of Lisinopril, Enalapril, Nitrendipine, Hydralazine, and Hydrochlorothiazide. Drug Intelligence & Clinical Pharmacy, 1988, 22, 546-550.	0.4	9
507	The Argon Contact Laser Scalpel: A Study of Its Effect on Atherosclerosis. Neurosurgery, 1987, 21, 861-866.	0.6	4
508	Serum Lidocaine Concentrations Following Application to the Oropharynx. Therapeutic Drug Monitoring, 1987, 9, 292-297.	1.0	2
509	Inhibition of human platelet and neutrophil function by piriprost (U-60,257). Prostaglandins, Leukotrienes, and Medicine, 1987, 29, 259-267.	0.8	5
510	Improvement in exercise performance with nisoldipine, a new second-generation calcium blocker, in stable angina patients. American Heart Journal, 1985, 110, 991-996.	1.2	42
511	Influence of calcium-channel blockers on platelet function and arachidonic acid metabolism. American Journal of Cardiology, 1985, 55, B158-B164.	0.7	71
512	Effects of nitrendipine and hydralazine on plasma catecholamines in essential hypertension. Clinical Pharmacology and Therapeutics, 1984, 36, 444-450.	2.3	22
513	Platelet function and biosynthesis of prostacyclin and thromboxane A2in whole blood after aspirin administration in human subjects. Journal of the American College of Cardiology, 1984, 4, 806-811.	1.2	30
514	Comparative efficacy and safety of lofexidine and clonidine in mild to moderately severe systemic hypertension. American Journal of Cardiology, 1984, 53, 787-790.	0.7	15
515	Prostaglandins: regulatory role in cardiovascular system and implications in ischemic heart disease. International Journal of Cardiology, 1983, 4, 249-259.	0.8	18
516	Nitrates for treatment of unstable angina pectoris and coronary vasospasm. American Journal of Medicine, 1983, 74, 40-44.	0.6	7
517	Optimal Lidocaine Dosing in Patients with Myocardial Infarction. Therapeutic Drug Monitoring, 1982, 4, 271-276.	1.0	3